The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody
Open Access
- 1 December 1994
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 70 (6) , 1126-1130
- https://doi.org/10.1038/bjc.1994.459
Abstract
Attachment of poly(ethylene glycol) (PEG) to proteins can greatly alter their pharmacological properties, including extending the plasma half-life and reducing immunogenicity, both of which are potentially beneficial to tumour targeting. IgG, F(ab')2 and Fab' fragments of the anti-CEA antibody A5B7 were chemically modified with PEG (M(r) 5,000), labelled with 125I and their pharmacokinetics compared with the unmodified forms in the LS174T colonic xenograft in nude mice. PEG modification of the intact antibody had little effect on biodistribution, although tumour localisation was slightly reduced. In contrast, similar modification of F(ab')2 and Fab'A5B7 significantly prolonged plasma half-life and increased radioantibody accumulation in the tumour and to a lesser extent in normal tissues, but reduced tissue to blood ratios. Prior to modification, Fab' A5B7 (M(r) 50,000) cleared more rapidly from the circulation than F(ab')2 (M(r) 100,000), but after PEG attachment their biodistributions converged, while the tumour to blood ratios were reduced and resembled that of the intact antibody. The enhanced tumour accumulation, reduced normal tissue to blood ratios and potentially reduced immunogenicity of fragments after PEG attachment may therefore prove superior to either unmodified fragments or intact antibody for antibody-targeted therapy, although the increased plasma half-life may necessitate the use of a clearance mechanism.Keywords
This publication has 12 references indexed in Scilit:
- Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.Published by Elsevier ,2021
- Comparative biodistributions of indium-111-labelled macrocycle chimeric B72.3 antibody conjugates in tumour-bearing miceBritish Journal of Cancer, 1994
- Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA) – implications for targeted therapyBritish Journal of Cancer, 1994
- Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft modelBritish Journal of Cancer, 1993
- Chemical engineering of the monoclonal antibody A7 by polyethylene glycol for targeting cancer chemotherapy.1991
- The effect of radiosensitizers on radio‐immunotherapy, using 131I‐Labelled anti‐cea antibodies in a human colonic xenograft modelInternational Journal of Cancer, 1991
- IODINE-131-LABELED MAB F(AB')2 FRAGMENTS ARE MORE EFFICIENT AND LESS TOXIC THAN INTACT ANTI-CEA ANTIBODIES IN RADIOIMMUNOTHERAPY OF LARGE HUMAN COLON-CARCINOMA GRAFTED IN NUDE-MICE1990
- Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancerBritish Journal of Cancer, 1989
- Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin ABritish Journal of Cancer, 1988
- Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograftEuropean Journal of Nuclear Medicine and Molecular Imaging, 1987